PURPOSE: To investigate the effect of heat shock protein (HSP) modulation on tumour coagulation by combining radiofrequency (RF) ablation with adjuvant liposomal quercetin and/or doxorubicin in a rat tumour model. METHODS: Sixty R3230 breast adenocarcinoma tumours/animals were used in this IACUC-approved study. Initially, 60 tumours (n=6, each subgroup) were randomised into five groups: (1) RF alone, (2) intravenous (IV) liposomal quercetin alone (1 mg/kg), (3) IV liposomal quercetin followed 24 h later with RF, (4) RF followed 15 min later by IV liposomal doxorubicin (8 mg/kg), (5) IV liposomal quercetin 24 h before RF followed by IV liposomal doxorubicin 15 min post-ablation. Animals were sacrificed 4 or 24 h post-treatment and gross coagulation diameters were compared. Next, immunohistochemistry staining was performed for Hsp70 and cleaved caspase-3 expression. Comparisons were performed by using Student t-tests or ANOVA. RESULTS: Combination RF-quercetin significantly increased coagulation size compared with either RF or liposomal quercetin alone (13.1±0.7 mm vs. 8.8±1.2 mm or 2.3±1.3 mm, respectively, P<0.001 for all comparisons). Triple therapy (quercetin-RF-doxorubicin) showed larger coagulation diameter (14.5±1.0 mm) at 24 h than quercetin-RF (P=0.016) or RF-doxorubicin (13.2±1.3 mm, P=0.042). Combination quercetin-RF decreased Hsp70 expression compared with RF alone at both 4 h (percentage of stained cells/hpf 22.4±13.9% vs. 38.8±16.1%, P<0.03) and 24 h (45.2±10.5% vs. 81.1±3.6%, P<0.001). Quercetin-RF increased cleaved caspase-3 expression at both 4 h (percentage of stained cells/hpf 50.7±13.4% vs. 41.9±15.1%, P<0.03) and 24 h (37.4±7.8% vs. 33.2±6.5%, P=0.045); with, triple therapy (quercetin-RF-doxorubicin) resulting in the highest levels of apoptosis (45.1±10.7%) at 24 h. Similar trends were observed for rim thickness. CONCLUSIONS: Suppression of HSP production using adjuvant liposomal quercetin can increase apoptosis and improve RF ablation-induced tumour destruction. Further increases in tumour coagulation can be seen including an additional anti-tumour adjuvant agent such as liposomal doxorubicin.
PURPOSE: To investigate the effect of heat shock protein (HSP) modulation on tumour coagulation by combining radiofrequency (RF) ablation with adjuvant liposomal quercetin and/or doxorubicin in a rattumour model. METHODS: Sixty R3230 breast adenocarcinoma tumours/animals were used in this IACUC-approved study. Initially, 60 tumours (n=6, each subgroup) were randomised into five groups: (1) RF alone, (2) intravenous (IV) liposomal quercetin alone (1 mg/kg), (3) IV liposomal quercetin followed 24 h later with RF, (4) RF followed 15 min later by IV liposomal doxorubicin (8 mg/kg), (5) IV liposomal quercetin 24 h before RF followed by IV liposomal doxorubicin 15 min post-ablation. Animals were sacrificed 4 or 24 h post-treatment and gross coagulation diameters were compared. Next, immunohistochemistry staining was performed for Hsp70 and cleaved caspase-3 expression. Comparisons were performed by using Student t-tests or ANOVA. RESULTS: Combination RF-quercetin significantly increased coagulation size compared with either RF or liposomal quercetin alone (13.1±0.7 mm vs. 8.8±1.2 mm or 2.3±1.3 mm, respectively, P<0.001 for all comparisons). Triple therapy (quercetin-RF-doxorubicin) showed larger coagulation diameter (14.5±1.0 mm) at 24 h than quercetin-RF (P=0.016) or RF-doxorubicin (13.2±1.3 mm, P=0.042). Combination quercetin-RF decreased Hsp70 expression compared with RF alone at both 4 h (percentage of stained cells/hpf 22.4±13.9% vs. 38.8±16.1%, P<0.03) and 24 h (45.2±10.5% vs. 81.1±3.6%, P<0.001). Quercetin-RF increased cleaved caspase-3 expression at both 4 h (percentage of stained cells/hpf 50.7±13.4% vs. 41.9±15.1%, P<0.03) and 24 h (37.4±7.8% vs. 33.2±6.5%, P=0.045); with, triple therapy (quercetin-RF-doxorubicin) resulting in the highest levels of apoptosis (45.1±10.7%) at 24 h. Similar trends were observed for rim thickness. CONCLUSIONS: Suppression of HSP production using adjuvant liposomal quercetin can increase apoptosis and improve RF ablation-induced tumour destruction. Further increases in tumour coagulation can be seen including an additional anti-tumour adjuvant agent such as liposomal doxorubicin.
Authors: B S Polla; S Kantengwa; D François; S Salvioli; C Franceschi; C Marsac; A Cossarizza Journal: Proc Natl Acad Sci U S A Date: 1996-06-25 Impact factor: 11.205
Authors: S N Goldberg; P F Hahn; K K Tanabe; P R Mueller; W Schima; C A Athanasoulis; C C Compton; L Solbiati; G S Gazelle Journal: J Vasc Interv Radiol Date: 1998 Jan-Feb Impact factor: 3.464
Authors: Weng-Lang Yang; Deepak G Nair; Ryouji Makizumi; George Gallos; Xuemei Ye; Rohit R Sharma; T S Ravikumar Journal: Ann Surg Oncol Date: 2004-04 Impact factor: 5.344
Authors: Wayne L Monsky; Jonathan B Kruskal; Anatoly N Lukyanov; Geoffrey D Girnun; Muneeb Ahmed; G Scott Gazelle; Juan Carlos Huertas; Keith E Stuart; Vladimir P Torchilin; S Nahum Goldberg Journal: Radiology Date: 2002-09 Impact factor: 11.105
Authors: T M Liszczak; E T Hedley-Whyte; J F Adams; D H Han; V S Kolluri; F X Vacanti; R C Heros; N T Zervas Journal: Acta Neuropathol Date: 1984 Impact factor: 17.088
Authors: S Nahum Goldberg; Ihab R Kamel; Jonathan B Kruskal; Kevin Reynolds; Wayne L Monsky; Keith E Stuart; Muneeb Ahmed; Vassilos Raptopoulos Journal: AJR Am J Roentgenol Date: 2002-07 Impact factor: 3.959
Authors: Gerd Schueller; Joachim Kettenbach; Roland Sedivy; Helga Bergmeister; Anton Stift; Josef Fried; Michael Gnant; Johannes Lammer Journal: Oncol Rep Date: 2004-09 Impact factor: 3.906
Authors: N E Blachere; Z Li; R Y Chandawarkar; R Suto; N S Jaikaria; S Basu; H Udono; P K Srivastava Journal: J Exp Med Date: 1997-10-20 Impact factor: 14.307
Authors: Scott M Thompson; Matthew R Callstrom; Bruce Knudsen; Jill L Anderson; Kim A Butters; Joseph P Grande; Lewis R Roberts; David A Woodrum Journal: Cardiovasc Intervent Radiol Date: 2012-08-25 Impact factor: 2.740
Authors: Marwan Moussa; S Nahum Goldberg; Beenish Tasawwar; Rupa R Sawant; Tatyana Levchenko; Gaurav Kumar; Vladimir P Torchilin; Muneeb Ahmed Journal: J Vasc Interv Radiol Date: 2013-05-09 Impact factor: 3.464